MD-Based EntreMed Inc.'s Anti-Cancer Drug to Be Studied at Duke Univ.
Posted on: Thursday, 30 June 2005, 21:00 CDT
EntreMed Inc., of Rockville, a clinical-stage biopharmaceutical company developing therapeutics primarily for the treatment of cancer and inflammatory diseases, said its novel anti-cancer drug, called Panzem NCD, will be studied by the Duke University Medical Center with a grant from the Susan G
. Komen Breast Cancer Foundation. Panzem is being used in combination with other medicines to determine its effect on chemotherapy-resistant breast cancer.Source: The Daily Record (Baltimore)
Related Articles
- Bathroom mould may hold key to finding cancer cure
- Altered Smallpox Vaccine May Fight Cancer
- Acupuncture May Have Place in Breast Cancer Treatment
- Blood Test May Measure Colon Cancer Risk
- Blood Marker Eyed in Colon Cancer Test
- Acupuncture a Salve for Colorectal Cancer?
- Abortion-Breast Cancer Link Deemed Untrue
- 'Sonic Hedgehog' Holds Clue to Lung Cancer
- Abortion, Breast Cancer Link Discounted
- American Cancer Society Takes on Fat
Rating: 3.6 / 5 (11 votes)
 |
 |
Rate this article:
User Comments (0)
RSS Feeds